The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Biomarkers of response and resistance to antiangiogenic therapy
Open accessAbstract
No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“no validated biomarkers are available to guide the use of antiangiogenic drugs7,126.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Cited by
Sorted by citations
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationBasic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationTumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,762
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Self-citationAngiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,486
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citationTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,074
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaı̈a, N. (2010) · Nature reviews. Immunology · doi:10.1038/nri2747 · Cited by 868
Senescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 758
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 680
Self-citationMetronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 666
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A. A., Fack, F., Thorsen, F. A., Taxt, T., Bartoš, M., Jiřík, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014480108 · Cited by 605
Rini, B. I., Cohen, D. P., Lu, D. R., Chen, I., Hariharan, S., Gore, M. E., Figlin, R. A., Baum, M. S., & Motzer, R. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr128 · Cited by 580
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 571
Self-citationPseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
da Cruz, L. C. H., Rodríguez, I., Domingues, R. C., Gasparetto, E. L., & Sorensen, A. G. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2397 · Cited by 551
Self-citationBatchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Self-citationVessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Frentzas, S., Simoneau, È., Bridgeman, V. L., Vermeulen, P., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A. C., Gao, Z., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 456
Maitland, M. L., Bakris, G. L., Black, H. R., Chen, H. X., Durand, J., Elliott, W. J., Ivy, S. P., Leier, C. V., Lindenfeld, J. M., Liu, G., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq091 · Cited by 416
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2636 · Cited by 414
Self-citationSorensen, A. G., Batchelor, T. T., Zhang, W., Chen, P.-J., Yeo, P., Wang, M., Jennings, D. L., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 395
Self-citationTargeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 363
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Self-citationAn overview of small-molecule inhibitors of VEGFR signaling
Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 356
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 352
Batchelor, T. T., Gerstner, E. R., Emblem, K. E., Duda, D. G., Kalpathy–Cramer, J., Snuderl, M., Ancukiewicz, M., Polaskova, P., Pinho, M. C., Jennings, D. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318022110 · Cited by 353
Self-citationPerfusion and vascular permeability: Basic concepts and measurement in DCE-CT and DCE-MRI
Cuénod, C. A., & Balvay, D. (2013) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2013.10.010 · Cited by 310
Cancer imaging by optical coherence tomography: preclinical progress and clinical potential
Vakoc, B. J., Fukumura, D., Jain, R. K., & Bouma, B. E. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3235 · Cited by 307
Self-citationOpacic, T., Dencks, S., Theek, B., Piepenbrock, M., Ackermann, D., Rix, A., Lammers, T., Stickeler, E., Delorme, S., Schmitz, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03973-8 · Cited by 315
Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
Lieu, C., Heymach, J., Overman, M., Tran, H., & Kopetz, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0659 · Cited by 286
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3366 · Cited by 268
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 259
Interleukin-6 Stimulates Defective Angiogenesis
Gopinathan, G., Milagre, C., Pearce, O. M. T., Reynolds, L. E., Hodivala-Dilke, K., Leinster, D. A., Zhong, H., Hollingsworth, R. E., Thompson, R., Whiteford, J. R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1227 · Cited by 249
PlGF: A Multitasking Cytokine with Disease-Restricted ActivityPreprint
Dewerchin, M. A., & Carmeliet, P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011056 · Cited by 247
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Metastatic Colorectal Cancer: From Improved Survival to Potential Cure
Gallagher, D. J., & Kemeny, N. E. (2010) · Oncology · doi:10.1159/000315730 · Cited by 241
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J. E., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 230
Forty-Year Journey of Angiogenesis Translational Research
Cao, Y., Arbiser, J. L., D’Amato, R. J., D'Amore, P. A., Ingber, D. E., Kerbel, R. S., Klagsbrun, M., Lim, S., Moses, M. A., Zetter, B. R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003149 · Cited by 226
Incio, J., Ligibel, J. A., McManus, D. T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S. M., Vardam, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0945 · Cited by 222
Self-citationLópez de Andrés, J., Griñán-Lisón, C., Jiménez, G., & Marchal, J. A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00966-3 · Cited by 207
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00838-y · Cited by 197
Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy
Gacche, R. N., & Meshram, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.002 · Cited by 203
Scagliotti, G. V., Vynnychenko, I. O., Park, K., Ichinose, Y., Kubota, K., Blackhall, F. H., Pirker, R., Galiulin, R., Ciuleanu, T., Sydorenko, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4987 · Cited by 184
Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
Self-citationThe VEGF family in cancer and antibody-based strategies for their inhibition
Sullivan, L. A., & Brekken, R. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11360 · Cited by 184
Scaling rules for diffusive drug delivery in tumor and normal tissues
Baish, J. W., Stylianopoulos, T., Lanning, R. M., Kamoun, W. S., Fukumura, D., Munn, L. L., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018154108 · Cited by 182
Self-citationDiastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J., Rosbrook, B., Bair, A. H., Ricart, A. D., Olszanski, A. J., Letrent, K. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2806 · Cited by 181
Mechanisms of resistance to antiangiogenesis therapy
Azam, F., Mehta, S., & Harris, A. L. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.020 · Cited by 188
CT Perfusion in Oncologic Imaging: A Useful Tool?
García‐Figueiras, R., Goh, V., Padhani, A. R., Baleato‐González, S., Garrido, M., León‐Mateos, L., & Gómez‐Caamaño, A. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.11.8476 · Cited by 175
Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
Yamada, K., Yamamoto, N., Yamada, Y., Nokihara, H., Fujiwara, Y., Hirata, T., Koizumi, F., Nishio, K., Koyama, N., & Tamura, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2638 · Cited by 162
Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P. C., Czito, B. G., Lin, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161
Self-citationZhu, A. X., Finn, R. S., Mulcahy, M. F., Gurtler, J., Sun, W., Schwartz, J. D., Dalal, R. P., Joshi, A., Hozak, R. R., Xu, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1442 · Cited by 164
Self-citationIntertwined regulation of angiogenesis and immunity by myeloid cells
Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 160
O’Connor, J. P. B., Carano, R. A. D., Clamp, A. R., Ross, J., Ho, C., Jackson, A., Parker, G. J. M., Rose, C. J., Peale, F. V., Jr., Friesenhahn, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0731 · Cited by 157
Pathological neoangiogenesis depends on oxidative stress regulation by ATM
Okuno, Y., Nakamura-Ishizu, A., Otsu, K., Suda, T., & Kubota, Y. (2012) · Nature Medicine · doi:10.1038/nm.2846 · Cited by 152
Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Li, Q., Wang, Y., Jia, W., Deng, H., Li, G., Deng, W., Chen, J., Kim, B. Y. S., Jiang, W., Liu, Q., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2179 · Cited by 156
Bevacizumab-induced hypertension: Clinical presentation and molecular understanding
Li, M., & Kroetz, D. L. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.012 · Cited by 153
VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)
Peng, F.-W., Liu, D., Zhang, Q., Xu, Y., & Shi, L. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1344215 · Cited by 152
Khoo, B. L., Grenci, G., Jing, T., Lim, Y. B., Lee, S. C., Thiery, J. P., Han, J., & Lim, C. T. (2016) · Science Advances · doi:10.1126/sciadv.1600274 · Cited by 147
Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
Pinato, D. J., Mauri, F. A., Ramakrishnan, R., Wahab, L., Lloyd, T., & Sharma, R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823f45c1 · Cited by 147
Blakeley, J. O., Ye, X., Duda, D. G., Halpin, C. F., Bergner, A. L., Muzikansky, A., Merker, V. L., Gerstner, E. R., Fayad, L. M., Ahlawat, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3817 · Cited by 143
Self-citationMechanisms of evasive resistance to anti-VEGF therapy in glioblastoma
Lu, K. V., & Bergers, G. (2012) · CNS Oncology · doi:10.2217/cns.12.36 · Cited by 143
Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy
Bagri, A., Berry, L., Gunter, B., Singh, M., Kasman, I. M., Damico, L. A., Xiang, H., Schmidt, M., Fuh, G., Hollister, B. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3100 · Cited by 140
Huang, H., Mallidi, S., Liu, J., Chiang, C.-T., Mai, Z., Goldschmidt, R., Ebrahim-Zadeh, N., Rizvi, I., & Hasan, T. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0391 · Cited by 141
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 140
Chae, S.-S., Kamoun, W. S., Farrar, C. T., Kirkpatrick, N. D., Niemeyer, E., de Graaf, A. M. A., Sorensen, A. G., Munn, L. L., Jain, R. K., & Fukumura, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3073 · Cited by 135
Self-citationLewin, M., Fartoux, L., Vignaud, A., Arrivé, L., Menu, Y., & Rosmorduc, O. (2010) · European Radiology · doi:10.1007/s00330-010-1914-4 · Cited by 137
Tvorogov, D., Anisimov, A., Zheng, W., Leppänen, V., Tammela, T., Laurinavičius, S., Holnthoner, W., Heloterä, H., Holopainen, T., Jeltsch, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.001 · Cited by 135
Towards novel paradigms for cancer therapy
Pavet, V., Portal, M. M., Moulin, J.-F., Herbrecht, R., & Gronemeyer, H. (2010) · Oncogene · doi:10.1038/onc.2010.460 · Cited by 135
Joaquim Bellmunt, B., González-Larriba, J. L., Prior, C., Maroto, P., Carles, J., Castellano, D., Mellado, B., Gallardo, E., Perez‐Gracia, J. L., Aguilar, G., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr023 · Cited by 127
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424024112 · Cited by 126
Self-citationUldrick, T. S., Wyvill, K. M., Kumar, P. P., O’Mahony, D., Bernstein, W., Aleman, K. O., Polizzotto, M. N., Steinberg, S. M., Pittaluga, S., Marshall, V. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6853 · Cited by 124
Yang, X., & Knopp, M. V. (2011) · BioMed Research International · doi:10.1155/2011/732848 · Cited by 123
Tomita, Y., Uemura, H., Fujimoto, H., Kanayama, H., Shinohara, N., Nakazawa, H., Imai, K., Umeyama, Y., Ozono, S., Naito, S., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.014 · Cited by 122
Vashist, Y. K., Loos, J., Dedow, J., Tachezy, M., Uzunoglu, G., Kutup, A., Yekebas, E. F., & Izbicki, J. R. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1383-7 · Cited by 121
Wong, H. K., Lahdenranta, J., Kamoun, W. S., Chan, A. W., McClatchey, A. I., Plotkin, S. R., Jain, R. K., & di Tomaso, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3107 · Cited by 121
Self-citationPhase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Tolaney, S. M., Ziehr, D. R., Guo, H., Ng, M. R., Barry, W. T., Higgins, M. J., Isakoff, S. J., Brock, J. E., Ivanova, E. V., Paweletz, C. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0229 · Cited by 118
Self-citationProgression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma
Nowosielski, M., Wiestler, B., Goebel, G., Hutterer, M., Schlemmer, H. P., Stockhammer, G., Wick, W., Bendszus, M., & Radbruch, A. (2014) · Neurology · doi:10.1212/wnl.0000000000000402 · Cited by 114
Lee, E. Q., Kaley, T. J., Duda, D. G., Schiff, D., Lassman, A. B., Wong, E. T., Mikkelsen, T., Purow, B. W., Muzikansky, A., Ancukiewicz, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3220 · Cited by 118
Self-citationFit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs
on behalf of the Bioanalysis and Quality Assurance (BAQA) Group of the ECMC, Cummings, J., Raynaud, F. I., Jones, J. L., Sugar, R., & Dive, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605910 · Cited by 112
Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R., Ravaud, A., et al. (2012) · Cancer · doi:10.1002/cncr.27632 · Cited by 110
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 108
Ronzoni, M., Manzoni, M., Mariucci, S., Loupakis, F., Brugnatelli, S., Bencardino, K. B., Rovati, B., Tinelli, C., Falcone, A., Villa, E., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq261 · Cited by 108
The VEGF pathway in lung cancer
Alevizakos, M., Kaltsas, S., & Syrigos, K. N. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2298-3 · Cited by 106
Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials
Mackey, J. R., Kerbel, R. S., Gelmon, K. A., McLeod, D., Chia, S., Rayson, D., Verma, S., Collins, L. L., Paterson, A. H. G., Robidoux, A., et al. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.002 · Cited by 104
Ceresoli, G. L., Zucali, P. A., Mencoboni, M., Botta, M., Grossi, F., Cortinovis, D. L., Zilembo, N., Ripa, C., Tiseo, M., Favaretto, A. G., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.368 · Cited by 106
Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis
Sareen, H., Ma, Y., Becker, T. M., Roberts, T. L., SOUZA, P. D., & Powter, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168835 · Cited by 104
Lankhorst, S., Kappers, M. H. W., van Esch, J. H. M., Danser, A. H. J., & van den Meiracker, A. H. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5244 · Cited by 104
Ribatti, D., Solimando, A. G., & Pezzella, F. (2021) · Cancers · doi:10.3390/cancers13143433 · Cited by 99
Bender, B. C., Schindler, E., & Friberg, L. E. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12258 · Cited by 99
Grivas, P. D., Daignault, S. D., Tagawa, S. T., Nanus, D. M., Stadler, W. M., Dreicer, R., Kohli, M., Petrylak, D. P., Vaughn, D. J., Bylow, K. A., et al. (2013) · Cancer · doi:10.1002/cncr.28477 · Cited by 98
Hosaka, K., Yang, Y., Seki, T., Du, Q., Xu, J., He, X., Wu, J., Zhang, Y., Morikawa, H., Nakamura, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17525-6 · Cited by 100
Donskov, F. N., Michaelson, M. D., Puzanov, I. J., Davis, M. P., Bjarnason, G. A., Motzer, R. J., Goldstein, D., Lin, X., Cohen, D. P., Wiltshire, R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.368 · Cited by 97
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 99
Duda, D. G., Willett, C. G., Ancukiewicz, M., di Tomaso, E., Shah, M., Czito, B. G., Bentley, R. C., Poleski, M. H., Lauwers, G. Y., Carroll, M. D., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0029 · Cited by 95
Self-citationMissiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 96
Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications
Scoazec, J. (2012) · Neuroendocrinology · doi:10.1159/000338371 · Cited by 95
Carbone, C., Moccia, T., Zhu, C., Paradiso, G., Budillon, A., Chiao, P. J., Abbruzzese, J. L., & Melisi, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1185 · Cited by 92
Metadata
- Authors
- Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G.
- Affiliations
- Harvard University (US)
- Duke Medical Center (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2009-06
- Volume
- 6
- Issue
- 6
- Pages
- 327-338
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC3057433
- OpenAlex
- W1993016882
- Cited by
- 572
- References
- 83
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 9 · 2023: 15 · 2022: 11 · 2021: 19 · 2020: 26 · 2019: 17 · 2018: 25 · 2017: 33 · 2016: 35 · 2015: 38 · 2014: 44 · 2013: 57 · 2012: 67
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA115767, R01CA57683, R01 CA 85140, R21CA117079, R01CA085140, R01CA057683, R21-CA 99237, P01CA080124, R21CA099237, R01CA126642, K24CA125440, R01CA129371, P01-CA-80124)
- National Center for Research Resources (P41-RR-14075, M01RR001066, P41RR014075, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- anti-angiogenic therapy, biomarkers, treatment response, drug resistance, patient selection, VEGF polymorphisms, type IV collagen, pharmacodynamic biomarkers, imaging biomarkers, Ktrans, placental growth factor, stromal cell-derived factor-1α, interleukin-6, tumor stroma
- MeSH terms
- Humans, Neoplasms, Neovascularization, Pathologic, Biomarkers, Tumor, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
